Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 14;9(1):7362.
doi: 10.1038/s41598-019-43621-9.

Tumour-treating fields (TTFields): Investigations on the mechanism of action by electromagnetic exposure of cells in telophase/cytokinesis

Affiliations

Tumour-treating fields (TTFields): Investigations on the mechanism of action by electromagnetic exposure of cells in telophase/cytokinesis

Lukas Berkelmann et al. Sci Rep. .

Abstract

Tumour-treating fields (TTFields) use alternating electric fields which interfere with dividing cells, thereby reducing tumour growth. Previous reports suggest that electrical forces on cell structure proteins interfered with the chromosome separation during mitosis and induced apoptosis. In the present report we evaluate electromagnetic exposure of cells in telophase/cytokinesis in order to further analyse the mechanism of action on cells. We performed numerical electromagnetic simulations to analyse the field distribution in a cell during different mitotic phases. Based thereon, we developed an electric lumped element model of the mitotic cell. Both the electromagnetic simulation and the lumped element model predict a local increase of the specific absorption rate (SAR) as a measure of the electromagnetically induced power absorption density at the mitotic furrow which may help to explain the anti-proliferative effect. In accordance with other reports, cell culture experiments confirmed that TTFields reduce the proliferation of different glioma cell lines in a field strength- and frequency-dependent manner. Furthermore, we found an additional dependence on the commutation time of the electrical fields. The report gives new insights into TTFields' anti-proliferative effect on tumours, which could help to improve future TTFields application systems.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
(a) Electrode setup for in-vitro TTFields exposure system. (b) Simulated electric fields in utilized setup, applied voltage Ve = 10 Vpp. Cells were cultivated within the area delineated by the red circle in the middle of the setup (d = 15 mm).
Figure 2
Figure 2
Calculated electric field distribution by application of a homogenous electrical field of E = 100 Vrms/m. Assumed parameters: cell diameter dc = 20 μm, membrane thickness and permittivity chosen to realize a capacitance of Cm,ges = 29 pF, relative permittivity of external medium and cytosol: εr = 80, conductivity  σ = 1.3 S/m. For the logarithmic (colour) scaling in dB we calculated EE0, with E0 the mean field strength in the surrounding medium.
Figure 3
Figure 3
Calculated local SAR in response to TTFields (E = 100 Vrms/m) applied at f = 100 kHz (s. Fig. 1). For the logarithmic scaling in dB we calculated SARSAR0, with SAR0 the mean SAR in the surrounding medium.
Figure 4
Figure 4
(a) Schematic representation of the lumped element model of a cell in telophase/cytokinesis exposed to an electric field polarised parallel to the longitudinal axis of the hourglass shape of the cell. See methods section for used element parameters. (b) Frequency-dependent currents in the cleavage furrow region as calculated with the lumped element model.
Figure 5
Figure 5
Simulated SAR in the cleavage furrow region.
Figure 6
Figure 6
Block diagram of the developed TTFields exposure setup.
Figure 7
Figure 7
Time- and field strength-dependent reduction of BT4Ca cell numbers after application of TTFields. Average cell numbers ± SEM from at least three replicates are shown. Significant differences compared to the control (cont., Student’s t test) are marked with asterisks: *P < 0.05, **P < 0.01.
Figure 8
Figure 8
Frequency-dependent reduction of BT4Ca cell numbers after application of TTFields (9 Vpp) for 72 h. Average cell numbers (% of control (cont.)) ± SEM from at least three replicates are shown. Significant differences compared to the control (Student’s t test) are marked with asterisks: *P < 0.05, **P < 0.01.
Figure 9
Figure 9
Commutation time-dependent reduction of BT4Ca cell numbers after application of TTFields (9 Vpp) for 72 h. Average cell numbers (% of control (cont.)) ± SEM from at least three replicates are shown. Significant differences compared to the control (Student’s t test) are marked with asterisks: *P < 0.05, **P < 0.01.
Figure 10
Figure 10
(a) Representative images of BT4Ca cells cultured in collagen I gels and stained for actin filaments (green) and nuclei (blue). (b) Reduction of the mean projection area of BT4Ca cell clusters cultured three-dimensionally in collagen I gels after application of TTFields (12 Vpp) for 72 h. Results are given as average ± SEM from five replicates.

Similar articles

Cited by

References

    1. Johnson DR, O’Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J. Neurooncol. 2012;107:359–364. doi: 10.1007/s11060-011-0749-4. - DOI - PubMed
    1. Adamson C, et al. Glioblastoma multiforme: a review of where we have been and where we are going. Expert. Opin. Investig. Drugs. 2009;18:1061–1083. doi: 10.1517/13543780903052764. - DOI - PubMed
    1. Ohgaki H. Epidemiology of brain tumors. Methods. Mol. Biol. 2009;472:323–342. doi: 10.1007/978-1-60327-492-0_14. - DOI - PubMed
    1. Stupp R, Roila F. & ESMO Guidelines Working Group. Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2009;20(Suppl 4):126–128. - PubMed
    1. Stupp R, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;31:2535–2543. doi: 10.1001/jama.2015.16669. - DOI - PubMed

Publication types